전체 프로그램

AntibodystaleEli LillyPhase 2

Cetuximab Sarotalocan Sodium (Cetuximab Sarotalocan Sodium)

Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma · FRα

CGTBiologicstaleJennifer Crombie, MDPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) Therapy Infusion)

Primary Mediastinal Large B-cell Lymphoma (PMBCL); Primary Mediastinal Large B Cell Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 67%임상시험 1상태 RECRUITING

CGTBiologicstaleNelson HamerschlakPhase 1

Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 (Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5

CGTBiologicstaleSecond Affiliated Hospital of G…Phase 1

Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells (Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells)

Stage IV Ovarian Cancer; Testis Cancer, Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5

ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Cobimetinib, dexamethasone, ixazomib, pomalidomide (Cobimetinib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

CGTBiologicstaleWashington University School of…Phase 2

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 1상태 DISCONTINUED

AntibodystaleJanssenPhase 2

Intravenously (Daratumumab, Daratumumab (Intravenously))

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

AntibodystaleJanssenPhase 2

임상시험 1상태 DISCONTINUED

daratumumab (Darzalex, Daratumumab with dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

AntibodystaleJanssenPhase 2

효능 ORR 18.4%임상시험 1상태 ACTIVE

daratumumab (Darzalex, Daratumumab, thalidomide and dexamethasone)

Relapse and / or Refractory Myeloma · FRα

AntibodystaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#항체#면역항체+3

AntibodystaleAmgenPhase 2

Xgeva (Denosumab, Denosumab (Xgeva))

Bone Cyst Aneurysmal; Pathological Fracture · FRα

ADCBiologicstaleMedImmune LLCPhase 1

효능 ORR 5%임상시험 1상태 ACTIVE

antibody drug conjugate (Dose Escalation, MEDI2228, ADC, Dose Escalation, MEDI2228, ADC (antibody drug conjugate))

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

ADCBiologicstaleMedImmune LLCPhase 1

antibody drug conjugate (Dose Expansion, MEDI2228, ADC, Dose Expansion, MEDI2228, ADC (antibody drug conjugate))

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

CGTBiologicstaleBeijing BiotechPhase 2

Dual-target CAR-NK cell product (Dual-target CAR-NK cell product)

Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

CGTBiologicstaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

CGTBiologicstaleKubota Vision Inc.Phase 1

Dose level 1 (EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy, EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1))

Refractory Glioblastoma; Recurrent Glioblastoma · FRα

CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

효능 ORR 15.4%임상시험 1상태 RECRUITING

Dose level 2 (EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy, EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2))

Refractory Glioblastoma; Recurrent Glioblastoma · FRα

CGTBiologicstaleGlaxoSmithKlinePhase 1

Dose level 3 (EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy, EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3))

Refractory Glioblastoma; Recurrent Glioblastoma · FRα

CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

효능 ORR 15.4%임상시험 1상태 RECRUITING

Dose level 4 (EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy, EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 4))

Refractory Glioblastoma; Recurrent Glioblastoma · FRα